The levels of EphA2+ EVs correlated with staging and tumor progression, with a discriminatory sensitivity only modestly diminished for early stages of PDAC vs non-cancerous diseases (91%) or pancreatitis (86%) comparisons. This evidence concerns the gene EPHA2 and neoplasm.